Title of article :
The Impact of Angiotensin-Converting Enzyme Inhibitor Therapy on the Extracellular Collagen Matrix During Left Ventricular Assist Device Support in Patients With End-Stage Heart Failure Original Research Article
Author/Authors :
Stefan Klotz، نويسنده , , A.H. Jan Danser، نويسنده , , Robert F. Foronjy، نويسنده , , Mehmet C. Oz، نويسنده , , Jie Wang، نويسنده , , Donna Mancini، نويسنده , , Jeanine D’Armiento، نويسنده , , Daniel Burkhoff، نويسنده ,
Issue Information :
روزنامه با شماره پیاپی سال 2007
Abstract :
Objectives
We hypothesized that angiotensin-converting enzyme inhibition (ACE-I) during left ventricular assist device (LVAD) support in patients with end-stage heart failure prevents potentially deleterious effects on the extracellular matrix.
Background
Left ventricular assist device-induced mechanical unloading increases myocardial collagen and stiffness and may contribute to the low rate of recovery.
Methods
Heart samples obtained before and after LVAD implantation were divided into groups depending on whether the patients received (n = 7) or did not receive (control; n = 15) ACE-I. At transplant, ex vivo pressure-volume relationships were measured and chamber and myocardial stiffness constants determined. Myocardial tissue content of angiotensin (Ang) I and II, matrix metalloproteinase (MMP)-1, tissue inhibitor of MMPs (TIMP)-1, and total and cross-linked collagen was measured.
Results
Duration of support was comparable between ACE-I and control subjects (96 ± 65 days vs. 109 ± 22 days). Pre-LVAD Ang I and II and total and cross-linked collagen were similar between groups. Post-LVAD, Ang II was reduced in the ACE-I group but increased in control subjects (181 ± 7 fmol/g vs. 262 ± 41 fmol/g; p < 0.05). Similarly, cross-linked collagen decreased during LVAD support in the ACE-I group. Left ventricular (LV) mass and myocardial stiffness were lower in the ACE-I group. ACE-I normalized the LV and right ventricular (RV) MMP-1/TIMP-1 ratio. Collagen content and characteristics of the RV were not affected by ACE-I.
Conclusions
ACE-I therapy was associated with decreased Ang II, myocardial collagen content, and myocardial stiffness during LVAD support. This is the first demonstration of a pharmacologic therapy that can impact myocardial properties during mechanical unloading, and it could foster new lines of investigation in strategies of enhancing myocardial recovery during LVAD support.
Keywords :
extracellular matrix , chronic heart failure , matrix metalloproteinase , angiotensin , ECM , MMP , CHF , RV , LV , left ventricle/ventricular , TIMP , right ventricle/ventricular , LVAD , left ventricular assist device , EDPVR , ACE-I , angiotensin-converting enzyme inhibition , Ang , passive end-diastolic pressure-volume relationship , tissue inhibitor of matrix metalloproteinases
Journal title :
JACC (Journal of the American College of Cardiology)
Journal title :
JACC (Journal of the American College of Cardiology)